Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron (RVT-901)

Our lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. We anticipate initiating an international Phase 3 registration program for vibegron in 2017.



Overactive Bladder (OAB)

Overactive bladder (OAB) is a condition that affects potentially 46 million American adults. The most common symptoms of OAB include the experience of sudden urges to urinate that cannot be controlled, frequent urination, and urinary incontinence due to involuntary contractions of the detrusor muscle. While several conditions may contribute to signs and symptoms of overactive bladder, the underlying cause of OAB remains unclear.



Latest News

The latest posts and articles

Urovant Sciences Appoints Keith A.…

Former CEO of Avanir Pharmaceuticals joins Roivant family of companies Plans to initiate confirmatory Phase…

Roivant Sciences Launches Urovant to…

Urovant has licensed vibegron, a Phase 3-ready selective β3-adrenergic agonist for the treatment of overactive…

Copyright 2017 © All Rights Reserved